Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01652729 · ClinicalTrials.gov registry record · Phase 3
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Phase 3 study of Diabetes Type 2, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 365
- Enrollment target
- 20
- Study locations
NCT01652729 is a Phase 3 study of Diabetes Type 2 that has completed, run by AstraZeneca. The registered enrollment target is 365 participants, below the 725-participant average among 21 other Diabetes Type 2 trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT01652729, a Phase 3 study of Diabetes Type 2, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 365 participants
- Enrollment target
- 20
- Study locations
Study Summary
To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by sitagliptin or placebo administered once daily for 28 weeks in subjects with type 2 diabetes mellitus.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG Exenatide once weekly suspension
Study Locations (20)
California
- Research Site - Beverly Hills
- Research Site - Buena Park
- Research Site - Chino
- Research Site - Chula Vista
- Research Site - Encinitas
- Research Site - Greenbrae
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - North Hollywood
- Research Site - Walnut Creek
- Research Site - West Hills
Florida
- Research Site - Boca Raton
- Research Site - Hialeah
- Research Site - Miami
- Research Site - Miami
- Research Site - Miami
Alabama
- Research Site - Birmingham
- Research Site - Huntsville
Arizona
- Research Site - Phoenix
- Research Site - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01652729
The ClinicalTrials.gov registry entry for NCT01652729 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 725-participant average among 21 other Diabetes Type 2 trials with a reported enrollment target (50% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Type 2 appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01652729 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01652729 about?
NCT01652729 is a clinical study titled "Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus". To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by sitagliptin or placebo administered once daily for 28 weeks in subjects with type 2 diabetes mellitus.
What is the current status of trial NCT01652729?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 365 participants. The study started on 2013-02. Estimated completion is 2014-04.
What conditions does trial NCT01652729 study?
This clinical trial studies the following conditions: Diabetes Type 2.
What interventions are being tested in trial NCT01652729?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), Exenatide once weekly suspension (DRUG).
Who is sponsoring clinical trial NCT01652729?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01652729 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
COMPLETED · Phase 3
-
Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix
COMPLETED · Phase 3
-
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
COMPLETED · Phase 3
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
RECRUITING · NA
-
Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age
RECRUITING · NA
-
Medically Intensive Nutrition Therapy Program for Obesity and Diabetes in a Low-income Population
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.